{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T07:08:19Z","timestamp":1767164899624,"version":"build-2238731810"},"reference-count":24,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2005,11,25]],"date-time":"2005-11-25T00:00:00Z","timestamp":1132876800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2005,12]]},"abstract":"<jats:p>\n                    <jats:bold>Abstract<\/jats:bold>\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>\n                      <jats:italic>Background<\/jats:italic>\n                      :\u2002\n                    <\/jats:bold>\n                    Asthma guidelines recommend increasing or doubling inhaled corticosteroid (ICS) dose to treat mild and moderate exacerbations of asthma in adults.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>\n                      <jats:italic>Aim<\/jats:italic>\n                      :\u2002\n                    <\/jats:bold>\n                    To: (i) compare the effectiveness of doubling existing daily ICS dose (fluticasone) with maintaining usual ICS dose and usual daily ICS dose accompanied by oral steroids (OS) (dexamethasone) during mild and moderately severe exacerbations of asthma in adults; (ii)\u2003examine determinants of success and failure; and (iii) compare side\u2010effect profiles.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>\n                      <jats:italic>Methods<\/jats:italic>\n                      :\u2002\n                    <\/jats:bold>\n                    A randomized, double\u2010blind, placebo\u2010controlled (double\u2010dummy), triple crossover trial. Participants acted as their own control. Outcome measures included treatment success\/failure, peak expiratory flow (PEF) after 7\u2003days therapy or at treatment failure, and side\u2010effects.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>\n                      <jats:italic>Results<\/jats:italic>\n                      :\u2002\n                    <\/jats:bold>\n                    From 22 participants (nine males and 13 females), 18 pairs of data were available for maintaining usual ICS versus doubling ICS and doubling ICS versus OS, and 19 for maintaining usual ICS versus OS. Median (fifth\u201395th percentile) age was 46.5 (32\u201364)\u2003years and forced expiratory volume in one second (FEV\n                    <jats:sub>1<\/jats:sub>\n                    ) 73% (29\u201397%) predicted. The outcome after doubling ICS was not superior to maintaining usual ICS, with 11 (61%) failures in both arms (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003=\u20030.66). OS, with only 5 (26%) failures, was superior to maintaining usual ICS with 12 (63%) failures (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003= 0.04), and to doubling ICS with 5 (28%) versus 11 (61%) failures (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003=\u20030.07). Median PEF (as percentage of run\u2010in best) at end\u2010points were 90.5% (57.1\u2013177.1) for OS, 78.3% (39.5\u2013103.1) for maintaining usual ICS and 77.9 (27.7\u2013110.3) for doubling ICS. Neither gender nor PEF at exacerbation were predictive of failure. Although doubling ICS was not an effective therapy overall, ICS dose at exacerbation were predictive of success in the doubling ICS arm (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003=\u20030.04). Treatment failures when doubling daily ICS dose were more common if achieved fluticasone dose was less than 2000\u2003\u00b5g (three of 11, 73%) compared to 2000\u2003\u00b5g or greater (eight of eight, 37.5%). Increasing age and the presence of an upper respiratory tract infection (URTI) were predictive of failure with OS. Side\u2010effects were more commonly reported with OS (52.6%) than doubling ICS (42.1%) or maintaining usual ICS (19.1%) with the most common being mood changes (36.8%), sleep disturbance (31.6%) and changes in appetite (26.3%).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>\n                      <jats:italic>Conclusions<\/jats:italic>\n                      :\u2002\n                    <\/jats:bold>\n                    Doubling daily ICS dose per\u2003se is not effective for the treatment of mild to moderately severe exacerbations of asthma in adults. Success may depend on achieved ICS dose. Oral steroids are effective, but side\u2010effects are common. A review of current guidelines may be warranted. (Intern Med J 2005; 35: 693\u2013698)\n                  <\/jats:p>","DOI":"10.1111\/j.1445-5994.2005.00972.x","type":"journal-article","created":{"date-parts":[[2005,11,25]],"date-time":"2005-11-25T05:03:38Z","timestamp":1132895018000},"page":"693-698","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Doubling daily inhaled corticosteroid dose is ineffective in mild to moderately severe attacks of asthma in adults"],"prefix":"10.1111","volume":"35","author":[{"given":"G.","family":"Rice\u2010McDonald","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Bowler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Staines","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,11,25]]},"reference":[{"key":"e_1_2_6_2_2","volume-title":"Asthma Management Handbook 1998.","author":"National Asthma Campaign","year":"1998"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199103213241202"},{"key":"e_1_2_6_4_2","doi-asserted-by":"crossref","unstructured":"RoweBH SpoonerCH DucharmeFM BretzlaffJA BotaGW.Corticosteroids for preventing relapse following acute exacerbations of asthma.Cochrane Database Syst Rev 2001; 1: CD000195. (Review)","DOI":"10.1002\/14651858.CD000195"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.292.6527.1045"},{"key":"e_1_2_6_6_2","doi-asserted-by":"crossref","unstructured":"ManserR ReidD AbramsonM.Corticosteroids for acute severe asthma in hospitalised patients.Cochrane Database Syst Rev 2001; 1: CD001740. (Review)","DOI":"10.1002\/14651858.CD001740"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)90134-3"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.151.5.7735580"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.96.09050880"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1994.tb01751.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1994.tb01752.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1136\/adc.79.1.12"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)15384-6"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2003.014936"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/thx.51.11.1087"},{"key":"e_1_2_6_16_2","first-page":"7","article-title":"A single high dose of inhaled corticosteroids: a possible treatment of asthma exacerbations","volume":"132","author":"Leuppi JD","year":"2002","journal-title":"Swiss Med Wkly"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1155\/2000\/587957"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.122.4.1208"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.119.3.720"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.10.1123"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62083-2"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1990.tb125350.x"},{"key":"e_1_2_6_23_2","unstructured":"Australian Bureau of Statistics.Australian Social Trends 1999 Health\u2003\u2013\u2003Mortality & Morbidity: Asthma.http:\/\/www.abs.gov.au"},{"key":"e_1_2_6_24_2","unstructured":"Australian Bureau of Statistics.Yearbook Australia 2002. 2002 Health Asthma.http:\/\/www.abs.gov.au"},{"key":"e_1_2_6_25_2","volume-title":"Understanding Asthma. A Management Companion","author":"Walls S","year":"2000"}],"updated-by":[{"DOI":"10.1111\/j.1445-5994.2006.01144.x","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2006,7,7]],"date-time":"2006-07-07T00:00:00Z","timestamp":1152230400000}}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1445-5994.2005.00972.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1445-5994.2005.00972.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T14:48:38Z","timestamp":1696862918000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1445-5994.2005.00972.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11,25]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["10.1111\/j.1445-5994.2005.00972.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1445-5994.2005.00972.x","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11,25]]},"assertion":[{"value":"2005-11-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}